Clinical Edge Journal Scan

Progression independent of relapse activity is a major cause of CDA in early relapsing MS


 

Key clinical point: Progression independent of relapse activity (PIRA) is a major contributor of confirmed disability accrual (CDA) in early relapsing-onset multiple sclerosis (MS), with age being a major determinant of the way CDA occurs.

Major finding: PIRA accounted for 27.6% of disability worsening events, whereas relapse-associated worsening ( RAW) accounted for 17.8% of events, with RAW being more frequent in younger ( hazard ratio [HR] 0.87 ) and PIRA in older ( HR 1.19; both P < .001 ) patients.

Study details: Findings are from a retrospective cohort analysis of 5169 patients with clinically isolated syndrome or early relapsing-remitting MS who were assessed within 1 year of onset and followed-up for ≥5 years.

Disclosures: No source of funding was declared. Some authors declared serving on advisory boards or receiving grants, travel compensation, speaker honoraria, or lecture and consulting fees from various sources .

Source: Portaccio E et al. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain. 2022 (Mar 24). Doi: 10.1093/brain/awac111

Recommended Reading

Clinical Edge Journal Scan Commentary: Multiple Sclerosis April 2022
ICYMI Multiple Sclerosis
Keto diet in MS tied to less disability, better quality of life
ICYMI Multiple Sclerosis
Neighborhood-level data sheds new light on racial and ethnic diversity in MS
ICYMI Multiple Sclerosis
The Enigma of MS Etiology: Find an Answer, Ask More Questions
ICYMI Multiple Sclerosis
Childhood abuse may increase risk of MS in women
ICYMI Multiple Sclerosis
MS: Fingolimod cessation safe if followed by prompt commencement of new therapy
ICYMI Multiple Sclerosis
PMS: pNfL could serve as biomarker for disability progression and drug response
ICYMI Multiple Sclerosis
Adverse childhood experiences associated with increased multiple sclerosis risk in women
ICYMI Multiple Sclerosis
Relapsing MS: Ofatumumab demonstrates superior benefit-risk profile than teriflunomide in RDTN patients
ICYMI Multiple Sclerosis
Multiple sclerosis: B-cell depleting therapies hinder nAb response following SARS-CoV-2 vaccination
ICYMI Multiple Sclerosis